Effect of aromatase inhibitor with LH-RH agonisit for tamoxifen resistant recurrent breast cancer

Effect of aromatase inhibitor with LH-RH agonisit for tamoxifen resistant recurrent breast cancer - AI with LH-RH study

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000004365

Enrollment

Registered

2010-10-12

Start date

2010-11-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Recurrent breast cancer

Interventions

recurrent after TAM traetment

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: ER positive recurrent breast cancer

Exclusion criteria

Exclusion criteria: male breast cancer

Design outcomes

Primary

Measure	Time frame
Clinical Benefit	—

Secondary

Measure	Time frame
time to progression and safety	—

Countries

Japan

Contacts

Public ContactMichi Miki

Institute of Health Bioscience Department of Thoracic endocrine surgery and Oncology

surgery2@clin.med.tokushima-u.ac.jp088-633-7143

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026